These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 11187111)

  • 1. SSRI safe with efavirenz.
    AIDS Patient Care STDS; 2000 Dec; 14(12):672-3. PubMed ID: 11187111
    [No Abstract]   [Full Text] [Related]  

  • 2. A review of abacavir and efavirenz: new antiretroviral drugs to treat HIV-1 infection.
    Wolbach J; Capoccia K
    Nurse Pract; 1999 Jun; 24(6):81-2, 87-90, 92. PubMed ID: 10431297
    [No Abstract]   [Full Text] [Related]  

  • 3. Effect of first line therapy including efavirenz and two nucleoside reverse transcriptase inhibitors in HIV-infected children.
    Funk MB; Notheis G; Schuster T; Elanjkal Z; von Hentig N; Stürmer M; Linde R; Dunsch D; Königs C; Wintergerst U; Kreuz W
    Eur J Med Res; 2005 Dec; 10(12):503-8. PubMed ID: 16356864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Penetration of efavirenz into the male genital tract: drug concentrations and antiviral activity in semen and blood of HIV-1-infected men.
    Taylor S; Reynolds H; Sabin CA; Drake SM; White DJ; Back DJ; Pillay D
    AIDS; 2001 Oct; 15(15):2051-3. PubMed ID: 11600838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of NNRTIs in antiretroviral-naïve patients.
    Arribas J
    Int J STD AIDS; 2001 Nov; 12 Suppl 4():3-9. PubMed ID: 11589822
    [No Abstract]   [Full Text] [Related]  

  • 6. High plasma levels of nelfinavir and efavirenz in two HIV-positive patients with hepatic disease.
    Maserati R; Villani P; Seminari E; Pan A; Lo Caputo S; Regazzi MB
    AIDS; 1999 May; 13(7):870-1. PubMed ID: 10357395
    [No Abstract]   [Full Text] [Related]  

  • 7. Efavirenz plasma concentrations and efficiency.
    López-Cortés LF; de Alarcón A; Viciana P
    AIDS; 2001 Jun; 15(9):1192-4. PubMed ID: 11416729
    [No Abstract]   [Full Text] [Related]  

  • 8. Switching from protease inhibitors to the non-nuke efavirenz.
    TreatmentUpdate; 2001; 12(12):3. PubMed ID: 11570089
    [No Abstract]   [Full Text] [Related]  

  • 9. Experience with efavirenz in end-stage renal disease.
    Das S; Ghanem M; Huengsberg M
    Int J STD AIDS; 2004 Feb; 15(2):143. PubMed ID: 15006080
    [No Abstract]   [Full Text] [Related]  

  • 10. Efficacy and safety of abacavir plus efavirenz as a salvage regimen in HIV-infected individuals after 48 weeks.
    Wasmuth JC; Herhaus C; Römer K; Salzberger B; Kaiser R; Schliefer K; Voigt E; Rockstroh JK
    AIDS; 2002 May; 16(7):1077-8. PubMed ID: 11953478
    [No Abstract]   [Full Text] [Related]  

  • 11. Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial.
    Hammer SM; Vaida F; Bennett KK; Holohan MK; Sheiner L; Eron JJ; Wheat LJ; Mitsuyasu RT; Gulick RM; Valentine FT; Aberg JA; Rogers MD; Karol CN; Saah AJ; Lewis RH; Bessen LJ; Brosgart C; DeGruttola V; Mellors JW;
    JAMA; 2002 Jul; 288(2):169-80. PubMed ID: 12095381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gynecomastia without lipodystrophy syndrome in HIV-infected men treated with efavirenz.
    Caso JA; Prieto Jde M; Casas E; Sanz J
    AIDS; 2001 Jul; 15(11):1447-8. PubMed ID: 11504970
    [No Abstract]   [Full Text] [Related]  

  • 13. Protease inhibitor-sparing regimens: new evidence strengthens position.
    Moyle GJ
    J Acquir Immune Defic Syndr; 2003 Jun; 33 Suppl 1():S17-25; quiz S26-8. PubMed ID: 12946062
    [No Abstract]   [Full Text] [Related]  

  • 14. [Efavirenz].
    Taéron C
    Rev Infirm; 2005 May; (111):37-8. PubMed ID: 15991644
    [No Abstract]   [Full Text] [Related]  

  • 15. Meeting notes from the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment. Trizivir vs. efavirenz: results from ACTG 5095.
    Feinberg J
    AIDS Clin Care; 2003 Sep; 15(9):78-9. PubMed ID: 14669723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenetics of efavirenz: adherence and virologic outcomes.
    Cennimo DJ
    Ann Intern Med; 2007 Dec; 147(11):817; author reply 817-8. PubMed ID: 18056676
    [No Abstract]   [Full Text] [Related]  

  • 17. Tolerance of efavirenz in children.
    Teglas JP; Quartier P; Treluyer JM; Burgard M; Gregoire V; Blanche S
    AIDS; 2001 Jan; 15(2):241-3. PubMed ID: 11216933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutations in HIV-1 reverse transcriptase potentially associated with hypersusceptibility to nonnucleoside reverse-transcriptase inhibitors: effect on response to efavirenz-based therapy in an urban observational cohort.
    Tozzi V; Zaccarelli M; Narciso P; Trotta MP; Ceccherini-Silberstein F; De Longis P; D'Offizi G; Forbici F; D'Arrigo R; Boumis E; Bellagamba R; Bonfigli S; Carvelli C; Antinori A; Perno CF
    J Infect Dis; 2004 May; 189(9):1688-95. PubMed ID: 15116307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Four-drug regimens may be better.
    AIDS Patient Care STDS; 2000 Dec; 14(12):671. PubMed ID: 11119435
    [No Abstract]   [Full Text] [Related]  

  • 20. Efavirenz decreases methadone blood concentrations.
    Marzolini C; Troillet N; Telenti A; Baumann P; Decosterd LA; Eap CB
    AIDS; 2000 Jun; 14(9):1291-2. PubMed ID: 10894303
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.